Health Economics›Myelodysplastic syndrome›Consolidation after first-line therapy

Consolidation after first-line therapy

Myelodysplastic syndrome · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Busulfan and Fludarabine, then allo HSCT Variant #08 Partial	—	R 30 308	—	~9.0 mo	—	~1	~R 30 308 PFS proxy · indirect	2
Busulfan and Cyclophosphamide, then allo HSCT Variant #02 Partial	—	R 13 162	—	—	—	~1	~R 13 162 PFS proxy · indirect	2

2 of 2 regimens shown